Taeko Hayakawa

发表

Personalized Cancer Immunotherapy: Immune Biomarkers and Combination Immunotherapy

T. Sakurai, Y. Kawakami, T. Kinoshita, 2016 .

SOCS3 deletion in effector T cells confers an anti-tumorigenic role of IL-6 to the pro-tumorigenic cytokine.

H. Nishimasu, O. Nureki, A. Yoshimura, 2023, Cell reports.

Enhanced anti‐tumor effects of the PD‐1 blockade combined with a highly absorptive form of curcumin targeting STAT3

Y. Kawakami, T. Yaguchi, T. Hayakawa, 2020, Cancer science.

Detection of residual disease in chronic myeloid leukemia utilizing genomic next generation sequencing reveals persistence of differentiated Ph+ B cells but not bone marrow stem/progenitors

Takashi Sasaki, R. Yamazaki, K. Takubo, 2020, Leukemia & lymphoma.

Development of Personalized Combination Cancer Immunotherapy Based on the Patients’ Immune Status

T. Sakurai, Y. Kawakami, T. Kinoshita, 2015 .

Reconstruction of Sjögren's syndrome-like sialadenitis by a defined disease specific gut-reactive single TCR and an autoantibody.

S. Chikuma, Kyoko Komai, Minako Ito, 2024, Clinical immunology.

Cancer Induced Immunosuppression and Its Modulation by Signal Inhibitors

T. Sakurai, Y. Kawakami, T. Kinoshita, 2015 .

NR4A ablation improves mitochondrial fitness for long persistence in human CAR-T cells against solid tumors

Tanakorn Srirat, K. Fukunaga, S. Mise-Omata, 2024, Journal for immunotherapy of cancer.

NR4a1/2 deletion promotes accumulation of TCF1+ stem-like precursors of exhausted CD8+ T cells in the tumor microenvironment.

S. Shichino, Minako Ito, Tanakorn Srirat, 2024, Cell reports.